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Background
Tobacco use accounts for the majority of urinary bladder
cancer (UBC) cases both in men and women. It is widely
accepted that smokers have increased risk of UBC [1-4].
An early diagnosis of UBC is crucial because patients
with superficial UBC have much better prognosis than
those with invasive UBC [1,2,4,5]. During the past years a
variety of urine based markers have been introduced for
screening of UBC. Nuclear matrix protein 22 (NMP22) is
a nuclear protein that is accountable for chromatid regu-
lation and cell separation during replication. The detec-
tion of NMP22 has been used from many clinical studies
to evaluate the possibility of UBC screening [2,6-8]. The
purpose of this review is to access the current literature
in order to determine the usefulness of NMP22 in
screening of UBC.
Materials and methods
A thorough search was conducted in MEDLINE using the
terms urinary bladder cancer OR urinary bladder neo-
plasm, NMP22 and screening. The following inclusion cri-
teria were adopted: i. studies that NMP22 was measured
in high risk patients without UBC and ii. studies that
NMP22 was compared between patients with known his-
tory of UBC and a control group without history of UBC.
We excluded studies that NMP22 was used only for the
surveillance of UBC.
Results
185 English-language articles were retrieved and 38 were
included in this study. Average total sensitivity of
NMP22 was 73.44 ± 15.11% and average total specificity
72.82 ± 16.27%. Positive predictive value (PPV) was
37.12 ± 26.11% and negative predictive value (NPV) was
87.47 ± 10.60%. Two studies did not report total specifi-
city or sensitivity rates. The majority of the reports
c o n c l u d e dt h a nN M P 2 2c a n n o tb eu s e df o rs c r e e n i n g
non-invasive UBC but benefits the screening for high
grade UBC in symptomatic patients. However there is no
study in the literature that indicates that NMP22 detec-
tion approaches level 1 of evidence in screening for UBC.
Based on the fact that the prevalence of UBC in asympto-
matic high risk patients without history of UBC is low
(4.0%), the diagnostic value of mass screening programs
in asymptomatic patients is questionable.
Conclusions
Detection of NMP22 is a non-invasive test that can be
easily applied and gives diagnostic answers very quickly
especially for tobacco-induced high grade tumors. NMP22
detection cannot replace cystoscopy. It is essential, more
studies to be conducted with careful selection of patients,
in order to find out, if NMP22 or a combination with
other markers are useful for diagnosing UBC [1,2,5].
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